jingsongling: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 32889 |
| SCHEMBL ID | 10601041 |
| MeSH ID | M0170920 |
| Synonym |
|---|
| aniline, 2,6-dimethyl-n-(2-thiazolinyl)- |
| xylazoline |
| n-(2,6-dimethylphenyl)-4,5-dihydro-2-thiazolamine |
| 2-(2,6-dimethylanilino)-2-thiazoline |
| jingsongling |
| 2-thiazolamine, n-(2,6-dimethylphenyl)-4,5-dihydro- |
| MAYBRIDGE4_003615 |
| HMS1531E07 |
| BRD-K26331361-001-01-5 |
| n-(2,6-dimethylphenyl)-4,5-dihydro-1,3-thiazol-2-amine |
| AKOS009281654 |
| mfcd01670142 |
| 2-thiazoline, 2-(2,6-xylidino)- |
| 25332-05-2 |
| SCHEMBL10601041 |
| DTXSID10179973 |
| CCG-246674 |
| 2-(2,6-dimethylphenyl)iminothiazolidine |
| 2-thiazolamine, n-(2,6-dimethylphenyl)-4,5-dihydro- (9ci) |
| n-(2,6-dimethylphenyl)-4,5-dihydrothiazol-2-amine |
| STARBLD0003036 |
| 1ST15571 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||